
Abott SL, Hanson DF, and Felland TD(2002): *Escherichia coli* O175:H7 generates a unique biochemical profile on Micro- Scan gram-negative identification. J Clin Microbiol, 32:823-824.

Acheson DWK, Levine MM, Kaper JB, and Keusch GT (1996): Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing *Vibrio cholerae* CVD 103-HgR. Infect Immun, 64:355-357.

Achi, R., L. Mata, X. Siles, and A. A. Lindberg. (1996): Immunomagnetic separation and PCR detection show *Shigella* to be common fecal agents in children from urban marginal communities of Costa Rica. J. Infect. 32:211– 218.

Ahmed R, Bopp C, and Borczyk A (1987): Phage-typing scheme for *Escherichia coli* O175:H7. J Infect Dis, 155: 806-809.

Albert MJ, Faruque SM, Faruque AS, Bettelheim KA, Neogi PK, Bhuiyan NA and Kaper JB (1996): Controlled study of cytolethal distending toxin- producing *Escherichia coli* infection in Bangladeshi children. J Clin Microbiol, 34:717-719.

Alejandro Lianos, MD, Jorge Lee, MD, Francisco Lo´pez, MD, Carmen Contreras, MSc, and Francesca Barletta (2012): Shiga toxin producing *E. coli* in Peruvian children with bloody diarrhea. The Pediatric Infectious Disease Journal • Volume 31, Number 3, March 2012 STEC in Peruvian Children With Bloody Diarrhea

Allos BM (2001): *Campylobacter jejuni* infections, update an emerging issues and trends. Clin Infect Dis, 32; 1201-6.

Altekruse SF, Stern NJ, Fields PI, and Swerdlow DL (1999): *Campylobacter jejuni*-an emerging foodborne pathogen. Emerg Infect Dis, 5:28-35.

Altwegg M and Bockemühl J (1998): *Escherichia* and *Shigella*. In Topley and Wilson’s Microbiology and Microbial Infections, Collier L,

Balows A, and Sussman M . 9th edition, New York, Oxford University Press, p 935-967.

Alvares-Olmos MI and Oberheman RA (2001): Probiotic agents and infectious disease:a modern perspective on a traditional therapy. Clin Infect Dis , 32: 1567-76.

Alvarez J, Sota M, Vivanco AB, Perales I, Cisterna R, Rementeria A, and Garaizar J (2004): Development of a multiplex PCR technique for detection and epidemiological typing of *Salmonella* in human clinical samples. J Clin Microbiol, 42(4): 1734–1738.

Andrade A, Girón JA, Amhaz JMK, Trabulsi LR, and Martinez MB (2002): Expression and characterization of flagella in non-motile enteroinvasive *Escherichia coli* isolated from diarrhea cases. J Infect Immun, 70 (10): 5882-5886.

Angulo, F. J., and D. L. Swerdlow. (2002): Bacterial enteric infections in persons infected with Human Immunodeficiency Virus. Clin. Infect. Dis. 21:S84–S93.

Aranda KR, Fagundes-Neto U and Scaletsky IC (2004): Evaluation of multiplex PCRs for diagnosis of infection with diarrheagenic *Escherichia coli* and *Shigella* spp. J Clin Microbiol, 42(12):5849-53.

Barth H, Aktories K, Popoff M and Stiles B (2004): "Binary bacterial toxins: biochemistry, biology, and applications of common *Clostridium* and *Bacillus* proteins". Microbiol Mol Biol Rev 68 (3): 373–402, table of contents. doi:10.1128/MMBR.68.3.373-402.2004. PMC 515256. PMID 15353562.

Bauer, MP; van Dissel JT and Kuijper, EJ (2009): "*Clostridium difficile*: controversies and approaches to management.". Current opinion in infectious diseases 22 (6): 517-24. PMID 19738464.

Bell, B.P., Goldoft, M., Griffin, P.M., Davis, M.A., Gordon, D.C., Tarr, P.I., Bartleson, C.A., Lewis, J.H., Barrett, T.J., Wells, J.G., (1994): A multistate outbreak of *Escherichia coli* O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 272, 1349–1353.

-
- Bennett-Wood VR, Russell J, Bordun AM, Johnson PD, and Robins-Browne RM (2004):** Detection of enterohemorrhagic *Escherichia coli* in patients attending hospitals in Melbourne, Australia. *Pathology*, 36 (4): 345-51.
- Bennett WE Jr and Tarr P (2009):** Enteric infections and diagnostic testing. *Curr Opin Gastroenterol* 2009;25:1–7.
- Bennish, M. L., M. A. Salam, R. Haider, and M. Barza. (1990):** Therapy for shigellosis II Randomized doubleblind comparison of ciprofloxacin and ampicillin. *J. Infect. Dis.* 162:711–716.
- Benjamin MM, and Datta AR (1995):** Acid tolerance of enterohemorrhagic *Escherichia coli*. *Appl Environ Microbiol*, 61:1669-1672.
- Betis F, Brest P, Hofman V, Guignot J, Kansau I, Rossi B, Servin A, and Hofman P (2006):** Afa/Dr diffusely adhering *Escherichia coli* infection in T84 cell monolayers induces increased neutrophil transepithelial migration, which in turn promotes cytokine-dependent upregulation of decay-accelerating factor (CD55), the receptor for Afa/Dr adhesins. *Infect Immun*, 71(4): 1774-83.
- Beutin L, Geier D, Steinrück H, Zimmermann S and Scheutz F (1993):** "Prevalence and some properties of verotoxin (Shiga-like toxin)-producing *Escherichia coli* in seven different species of healthy domestic animals". *Journal of clinical microbiology* 31 (9): 2483–8. PMC 265781. PMID 8408571.
- Beutin L, Krause G, Zimmermann S, Kaulfuss S, and Gleier K (2004):** Characterization of Shiga toxin-producing *Escherichia coli* strains isolated from human patients in Germany over a 3-year period. *J Clin Microbiol*, 42(3): 1099-108.
- Bhadra RK, Lior H, Misra SK, Pal SC, and Nair GB (1998):** Serotypes & biotypes of *Campylobacter jejuni* & *C. coli* from diverse sources in Calcutta. *Indian J Med Res*, 89:225-8.
- Bielaszewska M, Fell M, Greune L, Prager R, Fruth A, Tschäpe H, Alexander Schmidt MA, and Karch H (2004):** Characterization of

Cytolethal Distending Toxin Genes and Expression in Shiga Toxin-Producing *Escherichia coli* Strains of Non-O157 Serogroups Infect Immun, 72 (3): 1812-1816.

Bilge SS, Vary JC, Dowell SF, and Tarr PI (1996): Role of the *Escherichia coli* O157:H7 O side chain in adherence and analysis of an rfb locus. Infect Immun, 64:4795-4801.

Black, R. E., K. H. Brown, S. Becker, A. R. Alim, and I. Huq. (1982): Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II: Incidence of diarrhoea and association with known pathogens. Am. J. Epidemiol. 115:315–324.

Blanco, J.E., Blanco, M., Alonso, M.P., Mora, A., Dahbi, G., Coira, M.A., Blanco, J., (2004): Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing *Escherichia coli* isolates from human patients: prevalence in Lugo, Spain, from 1992 through 1999. J. Clin. Microbiol. 42, 311–319.

Bodhidatta L, Vithayasai N, Eimpokalarp B, Pitarangsi C, Serichantalergs O, and Isenbarger DW (2002): Bacterial enteric pathogens in children with acute dysentery in Thailand: increasing importance of quinolone-resistant *Campylobacter*. Southeast Asian J Trop Med Public Health, 33(4):725-7.

Bopp CA, Brenner FW, Fields PI, Wells JG, and Strockbine NA (2003): *Escherichia*, *Shigella*, and *Salmonella*. In Manual of Clinical Microbiology, Murray PR, Baron J, Jorgensen JH, Pfaller MA and Tenover FC, 8th edition, Washington D.C., ASM press, p 654-671.

Bottone EJ (1997): *Yersinia enterocolitica*: the charisma continues. Clin Microbiol Rev, 10:257-276.

Boudeau J, Glasser AL, Jullien S, Colombel JF, and Darfeuille-Michaud A (2003): Inhibitory effect of probiotic *Escherichia coli* strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive *E. coli* strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther, 18: 45-56.

-
- Bouzari S, Vatsla BR, and Varghese A (1992):** In vitro adherence property of cytolethal distending toxin (CLDT) producing enteropathogenic *Escherichia coli* (EPEC) strains and the effect of the toxin on rabbit intestine. *Microbiol Path*, 12: 153-157.
- Boyce TG, Swerdlow DL, and Griffin PM (1995):** Current concepts: *Escherichia coli* O157:H7 and the hemolytic-uremic syndrome. *N Engl J Med*, 333:364-368.
- Brenner, D. J., G. R. Fanning, G. V. Miklos, and A. G. Steigerwalt 1973:** Polynucleotide sequence relatedness among *Shigella* species. *Int. J. Syst. Bacteriol.* 23:1–7.
- Brooks GF, Butel JS and Morse SA (eds)(2004a):** Enteric Gram-negative rods (Enterobacteriaceae). In Jawetz, Melnick and Adelberg's Medical Microbiology, 23rd edition, New York, Appaleton and Lange, p 433-440.
- Brooks GF, Butel JS and Morse SA (eds) (2004b):** *Vibrios, Campylobacter, Helicobacter*, and associated bacteria. In Jawetz, Melnick and Adelberg's Medical Microbiology, 23rd edition, New York, Appaleton and Lange, p 269-279.
- Butler, T., M. R. Islam, and P. K. Bardham. (1984):** The leukemoid reaction in shigellosis. *Am. J. Dis. Child.* 138:162–165.
- Butler, T., P. Speelman, I. Kabir, and J. Banwell. (1986):** Colonic dysfunction during shigellosis. *J. Infect. Dis.* 154:817–824.
- Butler, T., M. R. Islam, M. A. K. Azad, and P. K. Jones. (1987):** Risk factors for development of hemolytic-uremic syndrome during shigellosis. *J. Pediatr.* 100:894–987.
- Byun Y, Ohmura M, and Fujihashi K (2006):** Nasal immunization with *E. coli* verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum-neutralizing antibodies. *Vaccine*, 9:2061-2070.
- Cam, P. D., T. Pal, and A. A. Lindberg. (1993):** Immune response against lipopolysaccharide and invasion plasmid- coded antigens of *shigellae* in Vietnamese and Swedish dysenteric patients. *J. Clin. Microbiol.* 31:454 – 457.

-
-
- Calderwood SB, Acheson DWK, Keusch GT, Barrett TJ, Griffin PM, Strockbine NA, Swaminathan B, Kaper JB, Levine MM, Kaplan BS, Karch H, O'Brien AD, Obrig TG, Takeda Y, Tarr PI, and Wachsmuth IK (1996):** Proposed new nomenclature for SLT (VT) family. ASM News, 62:118-119.
- Carpenter, K. P., and E. R. N. Cooke. (1965):** An attempt to find *shigellae* in wild primates. J. Comp. Pathol. 75:201–204.
- Carter, AO (1987):** A severe outbreak of *Escherichia coli* O157: H7 associated hemorrhagic colitis in a nursing home. N Eng T Med, 317: 1496-1500.
- Carvalho ACT, Ruiz-Palacios GM, Ramos-Cervantes P, Cervantes LE, Jiang X, and Pickering LK (2001):** Molecular characterization of invasive and noninvasive *Campylobacter jejuni* and *Campylobacter coli* isolates. J Clin Microbiol, 39(4): 1353–1359.
- Casalino, M., M. W. Yusuf, M. Nicoletti, P. Bazzicalupo, A. Coppo, B. Colonna, C. Cappelli, C. Bianchini, V. Falbo, and H. J. Ahmed. (1988):** A two-year study of enteric infectious associated with diarrheal diseases in children in urban Somalia. Trans. R. Soc. Trop. Med. Hyg. 82:637– 641.
- Castagliuolo I, Riegler MF, Valenick L, LaMont JT, and Pothoulakis C (1999):** *Saccharomyces Boulardii* protease inhibits the effects of *clostridium difficile* toxins A and B in human colonic mucosa. Infect Immun, 67: 302-7.
- Centers for Disease Control, and Prevention. (1994):** Health status of displaced persons following civil war in Burundi, December 1993–January 1994. MMWR 43: 701–703.
- Centers for Disease Control and Prevention (1994):** *Salmonella* surveillance annual summary 1992. Centers for Disease Control and Prevention, Atlanta, Ga.

-
- Centers for Disease Control and Prevention (2007):** Diagnosis of Shiga toxin-producing *Escherichia coli* by clinical diagnostic laboratories, STEC Clinical Diagnostics Working Group (in press).
- Ceponis PJ, Riff JD, and Sherman PM (2005):** Epithelial cell signaling responses to enterohemorrhagic *Escherichia coli* infection. Mem Inst Oswaldo, 100 (Suppl 1): 199-203.
- Cerna JF, Nataro JP, and Estrada-Garcia T (2003):** Multiplex PCR for detection of three plasmid-borne genes of enteroaggregative *Escherichia coli* strains. J Clin Microbiol, 41(5): 2138-40.
- Chandler WL, Jelacic S and Boster DR (2002):** Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002;346:23–32.
- Chart H , Smith HR and Scotland SM (1991):** Serological identification of E coli O 157: H7 infection in haemolytic uraemic syndrom . lancet 1991; 337: 138-140 .
- Ching JCY, Jones NL, Ceponis PJM, Karmali MA, and Sherman PM (2002):** *Escherichia coli* Shiga-like toxins induce apoptosis and cleavage of poly (ADP ribose) polymerase via in vitro activation of caspases. Infect Immun, 70:4669-4677.
- Chiu CH, Lin TY, and Ou JT (2000):** Age-related differences of nontyphoid *Salmonella* bacteremia in clinical presentation and outcome: association with specific serovars but not necessarily with the virulence plasmids. Clin Infec Dis, 30:239-240.
- Chiu CH, Su LH, and Chu C (2004):** *Salmonella* enterica serotype choleraesuis: epidemiology, pathogenesis, clinical disease and treatment. Clin Microbiol Rev, 17(2): 311-22.
- Church D. L., D. Emshey1, H. Semeniuk1, T. Lloyd and J. D. Pitout (2007):** Evaluation of CHROMagar O157 versus Sorbitol-MacConkey Medium for Routine Detection of *Escherichia coli* O157 in a Centralized. Regional Clinical Microbiology Laboratory Calgary Laboratory Services (CLS)1 and Departments of Pathology and

- Ciapetti G., E. Cenni, L. Pratelli and A. Pizzoferrato (1993):** In vitro evaluation of cell/biomaterial interaction by MTT assay Original Research Article Biomaterials, Volume 14, Issue 5, April 1993, Pages 359-364
- Clarke SC (2001):** Diarrheagenic *Escherichia coli*, an emerging problem. J Diagn Microbiol Infect Dis, 41:93-98.
- Clarke SC, Haigh RD, Freestone PPE and Williams PH (2003):** Virulence of Enteropathogenic *Escherichia coli*, a Global Pathogen. Clin Microbiol Rev, 16 (3): 365-378.
- Cleary TG (2003):** *Salmonella*. In Nelson Text book of Pediatrics. Behrman RE, Kliegman RM and Jenson HB (eds). 17th edition. Philadelphia, WB Saunders Company, p 912-919.
- Clemens, J., K. Kotloff, and B. Kay. (1999):** Generic protocol to estimate the burden of *Shigella* diarrhoea and dysenteric mortality. World Health Organization. Geneva
- Cockerill F, Beebakhee G, Soni R, and Sherman P (1996):** Polysaccharide side chains are not required for attaching and effacing adhesion of *Escherichia coli* O157:H7. Infect Immun, 64: 3196-3200.
- Coia JE (1998):** Clinical, microbiological, and epidemiological aspects of *Escherichia coli* O157: H7 infection. FEMS M Immunol Microbiol, 20:1-9.
- Coimbra, R. S., F. Grimont, and P. A. D. Grimont. (1999):** Identification of *Shigella* serotypes by restriction of amplified O-antigen gene cluster. Res. Microbiol. 150: 543–553.
- Coker AO, Isokpehi RD, Thomas BN, Amisu KO, and Obi CL (2002):** Human campylobacteriosis in developing countries. Emerg Infect Dis, 8(3): 237-44.

Collee, J. G and Marr. W. (1996): Culture of bacteria In: Collee, J.G. Marmion, B.P., Fraser, A.G. and Simmons, A. (eds) Mackie and McCartney Practical Medical Microbiology Vol 1, 4th edition. Churchill livingstone. P. 113-129.

Collee JG, Duguid JP, Fraser AG, Marmion BP, and Simmons A (1996): Laboratory strategy in the diagnosis of infective syndromes. In Mackie and McCartney Practical Medical Microbiology, Colle JG, Fraser AG, Marmion BP and Simmons A, 14th edition, New York, Churchill Livingstone, p53-94.

Cornelis GR, Boland A, Boyd AP, Geuijen C, Iriarte M, Neyt C, Sory MP, and Stainier I (1998): The virulence plasmid of *Yersinia*, an antihost genome. Microbiol Mol Biol Rev, 62:1315-1352.

Cortes-Bratti X, Frisan T, and Thelestam M (2001): The cytolethal distending toxins induce DNA damage and cell cycle arrest. Toxicon, 39:1729-1736.

Crepin VF, Prasannan S, Shaw RK, Wilson RK, Creasey E, Abe CM, Knutton S, Frankel G, and Matthews S. (2005): Structural and functional studies of the enteropathogenic *Escherichia coli* type III needle complex protein EscJ. Mol Microbiol, 55(6): 1658-70.

Crichton PM (1996): Enterobacteriaceae: *Escherichia*, *Klebsiella*, *Proteus* and other genera. In Mackie and McCartney Practical Medical Microbiology, Colle JG, Fraser AG, Marmion BP and Simmons A, 14th edition, New York, Churchill Livingstone, p361-384.

Crump JA, Sulka AC, Langer AJ, Schaben C, Crielly AS, Gage R, Baysinger M, Moll M, Withers G, Toney DM, Hunter SB, Hoekstra RM, Wong SK, Griffin PM, and Van Gilder TG (2002): An outbreak of *Escherichia coli* O157:H7 infections among visitors to a dairy farm. N Engl J Med. 347(8): 555-60.

Cunha BA (2010): Cytomegalovirus pneumonia: community-acquired pneumonia in immunocompetent hosts. *Infect Dis Clin North Am*. Mar 2010;24(1):147-58.

-
- Curry J (2007):** "Pseudomembranous Colitis". eMedicine. WebMD. Retrieved 2008-11-17.
- Darwin KH and Miller VL (1999):** Molecular basis of the interaction of *Salmonella* with the intestinal mucosa. Clin Microbiol Rev, 12 (3): 405-428.
- Davies N.E.C.G, A.S. Karstaedt (2008):** *Shigella* bacteraemia over a decade in Soweto, South Africa Original Research Article Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 102, Issue 12, December 2008, Pages 1269-1273.
- Deayton JR, Prof Sabin CA, Johnson MA, Emery VC, Wilson P and Griffiths PD (2004):** Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. *Lancet*. Jun 26 2004;363(9427):2116-21.
- Deng W, Li Y, Hardwidge PR, Frey EA, Pfuetzner RA, Lee S, Gruenheid S, Strynacka NC, Puente JL, and Finlay BB (2005):** Regulation of type III secretion hierarchy of translocators and effectors in attaching and effacing bacterial pathogens. Infect Immun, 73(4): 2135-46.
- Denno DM, Keene WE and Hutter CM (2009):** A tri-county comprehensive assessment of risk factors for sporadic bacterial reportable enteric infections in children. J Infect Dis 2009;199:467–476.
- DeVinney R, Gauthier A, Abe A, and Finlay BB (1999):** Enteropathogenic *Escherichia coli*: a pathogen that inserts its own receptor into host cells. Cell Mol Life Sci, 55(6-7):961-76.
- Donnenberg MS and Nataro JP (1995):** Methods for studying adhesion of diarrheagenic *Escherichia coli*. Methods Enzymol, (253): 324-336.
- Donnenberg MS, Tacket CO, SP James, G. Losonsky G, Nataro JP, Wasserman SS, Kaper JB, and Levine MM (1993):** Role of the eaeA gene in experimental enteropathogenic *Escherichia coli* infection. J Clin Invest, 92:1412-1417.

-
- Donnenberg MS and Whittam TS (2001):** Pathogenesis and evolution of virulence in enteropathogenic and enterohemorrhagic *Escherichia coli*. J Clin Invest, 107: 539-548.
- Dritz, S. K., and A. F. Black. (1974):** *Shigella* enteritis venerally transmitted. N. Engl. J. Med. 291:1194.
- Drusin, L. M., G. Genvert, and B. Topf-Olstein. (1976):** Shigellosis: Another sexually transmitted disease?. Br. J. Vener. Dis. 52:348–350
- Duguid JP (1996):** *Shigella*. In Mackie and McCartney Practical Medical Microbiology, Colle JG, Fraser AG, Marmion BP and Simmons A, 14th edition, New York, Churchill Livingstone, p 405-412.
- Dumenil, G., P. J. Sansonetti, and G. Tran Van Nhieu. (2000):** Src tyrosine kinase activity down-regulates Rho-dependent responses during *Shigella* entry into epithelial cells and stress fiber formation. J. Cell Sci. 113:71–80
- Dundas S, Todd WT, Stewart AJ, Murdoch PS, Chaudhuri AK, and Hutchinson SJ (2002):** The central Scotland *Escherichia coli* O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis, 35 (3): 346-7.
- DuPont, H. L., R. B. Hornick, A. T. Dawkins, M. J. Snyder, and S. B. Formal. (1989):** The response of man to virulent *Shigella flexneri* 2a. J. Infect. Dis. 119:296–299.
- Du Pont HL (1997):** Guidelines on acute infectious diarrhea in adults. The practice parameters committee of the American College of Gastroenterology, 92: 1962-1975.
- Dutta, P., D. Dutta, S. K. Bhattacharya, D. Sen, U. Mitra, A. R. Ghosh, M. Lahiri, and B. C. Deb. (1989):** Clinical and bacteriological profiles of shigellosis in Calcutta before and after an epidemic (1984–87). Ind. J. Med. Res.89:132–137.
- Dylla BL, Vetter EA, Hughes JG, and Cockerill FR (1995):** Evaluation of an immunoassay for direct detection of *Escherichia coli* in stool specimens. J Clin Microbiol, 33: 222-224.

Echeverria, P., O. Sethabutr, and C. Pitarangsi. (2004): Microbiology and diagnosis of infections with *Shigella* and Enteroinvasive *Escherichia coli*. Rev. Infect. Dis. 13:S220–S225.

Edward A. Belongia,1 Po-Huang Chyou,1 Robert T. Greenlee,1 Guillermo Perez-Perez and 2 William F. Bibb (2003): Diarrhea Incidence and Farm-Related Risk Factors for *Escherichia coli* O157:H7 and *Campylobacter jejuni* Antibodies among Rural Children 1- Epidemiology Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin; 2- Departments of Medicine and Microbiology, New York University, New York, New York; JID 2003:187 (1 May)

Elliott DE (1996): Schistosomiasis. Pathophysiology, diagnosis, and treatment. Gastroenterol Clin North Am 1996;25:599–625.

El-Sheikh SM and El-Assouli SM (2001): Prevalence of viral, bacterial and parasitic enteropathogens among young children with acute diarrhoea in Jeddah, Saudi Arabia. J Health Popul Nutr, 19(1): 25-30.

Endo, Y., K. Tsurugi, T. Yutsudo, Y. Takeda, T. Ogasawara, and K. Igarashi. (1988): Site of action of Vero toxin (VT2) from *Escherichia coli* O157:H7 and of Shiga toxin on eukaryotic ribosomes: RNA N glycosidases activity of the toxins. Eur. J. Biochem. 171:45–50.

Farthing MJG, Kelly MP, Veitch AM (2000): Recently recognized microbial enteropathies and HIV infection. J Antimicrob Chemother 2000;37(Suppl. B):61–70.

Fedorak RN and Madsen KL (2004): Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol, 20: 148-155.

Fernandes RM, Carbonare SB, Carneiro-Sampaio MM, and Trabulsi LR (2001): Inhibition of enteroaggregative *Escherichia coli* adhesion to HEp-2 cells by secretory immunoglobulin A from human colostrum. Pediatr Infect Dis J, 20(7): 672-8

-
- Fleckenstein JM, Lindler LE, Elsinghorst EA, and Dale JB (2000):** Identification of a gene within a pathogenicity island of enterotoxigenic *Escherichia coli* H10407 required for maximal secretion of the heat-labile enterotoxin. *Infect Immun*, 68:2766-2774.
- Foley SL, Simjees S, Meng J, White DG, McDermott PF, and Zhao S (2004):** evaluation of molecular typing methods for *Escherichia coli* O157:H7 isolates from cattle, food, and humans. *J Food Prot*, 67 (4): 651-7.
- Fontaine, A., J. Arondel, and P. J. Sansonetti. (1988):** Role of Shiga toxin in the pathogenesis of bacillary dysentery as studied with a Tox-mutant of *Shigella dysenteriae* 1. *Infect. Immun*. 56:3099–3109.
- Fredriksson-Ahomaa M and Korkeala H (2003):** Low occurrence of pathogenic *Yersinia enterocolitica* in clinical, food, and environmental samples: a Methodological Problem. *Clin Microbiol Rev*, 16 (2): 220-229.
- Froehlich B, Holtzapfel E, Read TD and Scott JR (2004):** Horizontal transfer of CS1 Pilin genes of enterotoxigenic *Escherichia coli*. *J Bacteriol*, 186(10): 3230-3237.
- Frye R (2004):** Bacterial Gastroenteritis. Available at <http://www.e.medicine.com>
- Gaillard J-L. – La (1998):** “ maladie du hamburger ” à *Escherichia coli* O157 :H7 – Médecine thérapeutique, 1998, vol. 4, n°9, p. 743-747.
- Gangarosa, E. J. 1970. Epidemic Shiga bacillus dysentery in Central America II Epidemiology studies in (1969):** *J. Infect. Dis.* 122:181–190.
- Germani, Y., P. Cumin, E. Tedjouka, N. Chonaibon, J. Morvan, and P. Martin. (1998a):** Enterohemorrhagic *Escherichia coli* and *Shigella dysenteriae* type 1 in Ngoila (Cameroun) during an outbreak of bloody diarrhea. *Lancet* 352:625–626.
- Germani, Y. P., M. Minssart, S. Vohito, P. Yassibanda, D. Glazion, P. Hocquet, J. Berthélémy, and J. Morvan. (1998b):** Etiologies of acute,

persistent and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to Human Immunodeficiency Virus serostatus. *Am. J. Trop. Med. Hyg.* 59(6):1008–1014

Goldberg MB, Boyko SA, Butterton JR, Stoebner JA, Payne SM, and Calderwood SB (1992): Characterization of a *Vibrio cholerae* virulence factor homologous to the family of TonB-dependent proteins. *Mol Microbiol*, 6:2407-2418.

Goldwater PN and Bettelheim KA (1994): The role of enterohaemorrhagic *E. coli* serotypes other than O157:H7 as causes of disease, In Karmali MA, and Goglio AG Recent advances in verocytotoxin-producing *Escherichia coli* infections. 1st edition, Elsevier Science B.V., Amsterdam, The Netherlands, p 57-60.

Goma Epidemiology Group. (1995): Public health impact of Rwandan refugee crisis: What happened in Goma, Zaire, in July, 1994?. *Lancet* 345:339–344

Gomez and Cleary (2003b): *Yersinia* species. In Principles and Practice of Pediatric Infectious Diseases, Long SS, Pickering LK and Prober CG, 2nd edition, Churchill Livingstone, p 839-844.

Goodman LJ, Manuselis G, and Mahon CR (1995): Gastrointestinal infections and food poisoning. In Diagnostic Microbiology. Mahon CR and Manuselis G (eds). WB Saunders Company, p 895-914.

Goosney DL, De Vinney R, and Finlay BB (2001): Recruitment of cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic *Escherichia coli* pedestals. *Infect Immun*, 69: 3315-3322.

Gordillo ME, Reeve GR, Pappas J, Mathewson JJ, DuPont HL, and Murray BE (1992): Molecular characterization of strains of enteroinvasive *Escherichia coli* O143, including isolates from a large outbreak in Houston. Texas. *J Clin Microbiol*, 30:889-893.

Gore JJ, Surawicz C (2003): Severe acute diarrhea. *Gastroenterol Clin North Am* 2003;32:1249–1267.

-
- Greenwald DA, Brandt LJ and Reinus JF (2001):** Ischemic bowel disease in the elderly. *Gastroenterol Clin North Am* 2001;30:445–473.
- Griffin PM and Tauxe RV (1991):** The epidemiology of infections caused by *Escherichia coli* O157: H7, other enterohemorrhagic *E. coli*, and the associated hemolytic uremic syndrome. *Epidemiol Rev*, 13: 60-98.
- Guerrant RL, Van Gilder T, and Steiner TS (2001):** Practice guidelines for the management of infectious diarrhea. *Clin Infect Dis*, 32: 331-350.
- Hale TL and Keusch GT (1996):** Shigella. in: *Baron's Medical Microbiology* (Baron S et al., eds.) (4th ed.). Univ of Texas Medical Branch. ISBN 0-9631172-1-1
- Halsey J (2008):** "Current and future treatment modalities for *Clostridium difficile*-associated disease". *Am J Health Syst Pharm* 65 (8): 705–15. doi:10.2146/ajhp070077. PMID 18387898.
- Haltalin, K. C., H. T. Kusmiesz, L. V. Hinton, and J. D. Nelson. (2006):** Treatment of acute diarrhea in outpatients: Double-blind study comparing ampicillin and placebo. *Am. J. Dis. Child.* 124:554–561.
- Haque R, Huston CD, Hughes M, Houpt E and Petri WA Jr(2003):** Amebiasis. *N Engl J Med* 2003;348:1565–1573.
- Harrison LM, van den Hoogen C, van Haaften WC, and Tesh VL (2005):** Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides. *Infect Immun*, 73(1):403-12.
- Hart CA, Batt RM and Saunders JR (1993):** Diarrhea caused by *Escherichia coli*. *Ann Trop pediatr*, 13: 121-131.
- Heikkila, E., A. Sintonen, M. Jahkola, M. Fling, L. Sundstrom, and P. Huovinen. (1990):** Increase of trimethoprim resistance among *Shigella* species, 1975–1988: Analysis of resistance mechanisms. *J. Infect. Dis.* 161:1242–1248.

-
- Heresi GP and Murphy JR (2003):** *Campylobacter*. In Nelson Text book of Pediatrics, Behrman RE, Kliegman RM and Jenson HB, 17th edition, Philadelphia, WB Saunders Company, p 926-929.
- Heyneman D (2004):** Medical parasitology. In Jawetz, Melnick and Adelberg's Medical Microbiology, Brooks GF, Butel JS and Morse SA, 23rd edition, New York, Appaleton and Lange, p 561-595.
- Holme, R., (2003):** Drinking water contamination in Walkerton, Ontario: positive resolutions from a tragic event. Water Sci. Technol. 47, 1–6.
- Holtz R. Lori, Marguerite A. Neill And Phillip I. Tarr (2009):** Acute Bloody Diarrhea: A Medical Emergency for Patients of All Ages. Division of Gastroenterology and Nutrition, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri; Division of Infectious Diseases, Department of Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island 2009;136:1887–1898
- Howell MD, Novack V and Grgurich P (2010):** "Iatrogenic gastric acid suppression and the risk of nosocomial *Clostridium difficile* infection". Arch. Intern. Med. **170** (9): 784–90doi:10.1001/archinternmed.2010.89. PMID 20458086
- Huang DB, DuPont HL, Jiang ZD, Carlin L, and Okhuysen PC (2004):** Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic *Escherichia coli*. Clin Diagn Lab Immun, 11(3): 548-551.
- Hudault S, Guignot J and Servin AL (2001):** "Escherichia coli strains colonising the gastrointestinal tract protect germfree mice against *Salmonella typhimurium* infection". Gut 49 (1): 47–55. doi:10.1136/gut.49.1.47. PMC 1728375. PMID 11413110.
- Huilan, S., L. G. Zhen, M. M. Mathan, M. M. Mathew, J. Olate, R. Espejo, U. Khin Maung, M. A. Ghafoor, M. A. Khan, and Z. Sami. (1991):** Etiology of acute diarrhea among children in developing countries: A multicentre study in five countries. Bull. WHO 69:549–555.

-
- Hunt CM, Harvey JA, Youngs ER, Irwin ST and Reid TM (1989):** Clinical and pathological variability of infection by enterohaemorrhagic (Vero cytotoxin producing) *Escherichia coli*. J Clin Pathol 1989;42:847– 852.
- Hyams, K. C., A. L. Bourgeois, B. R. Merrell, P. Rozmajzl, J. Escamilla, S. A. Thornton, G. M. Wasserman, A. Burke, P. Echeverria, and K. Y. Green. (1991):** Diarrheal disease during Operation Desert Shield. N. Engl. J. Med. 325:1423–1428.
- Islam, M. S., M. Z. Hassain, S. I. Khan, A. Felsenstein, R. B. Sack, and M. Albert. (1997):** Detection of non-cultivable *Shigella dysenteriae* type 1 from artificially contaminated volunteer's fingers using fluorescent antibody and PCR techniques. J. Diarrhoeal Dis. Res. 15:65–70.
- Islam, M. S., M. S. Hossain, M. K. Hasan, M. M. Rahman, G. Fuchs, D. Mahalanabis, A. H. Baqui, and M. J. Albert. (1998):** Detection of *shigellae* from stools of dysentery CHAPTER 3.3.6 The Genus *Shigella* 119 patients by culture and polymerase chain reaction techniques. J. Diarrhoeal Dis. Res. 16:248–251.
- Jacobs DO (2007):** Clinical practice. Diverticulitis. N Engl J Med 2007; 357:2057–2066.
- Jallat C, Livrelli V, Darfeuille-Michaud A, Rich C, and Joly B (1993):** *Escherichia coli* strains involved in diarrhea in France: high prevalence and heterogeneity of diffusely adhering strains. J Clin Microbiol, 31:2031-2037.
- Janka A, Bielaszewska M, Dobrindt U, Greune L, Schmidt MA, and Karch H (2003):** The cytolethal distending toxin (cdt) gene cluster in enterohemorrhagic *Escherichia coli* O157: H and O157:H7: characterization and evolutionary considerations. Infect Immun, 71:3634-3638.
- Jelacic, J.K., Damrow, T., Chen, G.S., Jelacic, S., Bielaszewska, M., Ciol, M., Carvalho, H.M., Melton-Celsa, A.R., O'Brien, A.D., Tarr, P.I., (2003):** Shiga toxin-producing *Escherichia coli* in Montana: bacterial genotypes and clinical profiles. J. Infect. Dis. 188, 719–729.

-
- Jiang ZD, Greenberg D, Nataro JP, Steffen R, and DuPont HL (2002):** Rate of Occurrence and Pathogenic Effect of Enteroaggregative *Escherichia coli* Virulence Factors in International Travelers. *J Clin Microbiol*, 40 (11): 4185- 4190.
- Johnson RP, Clarke RC, Wilson JB, Read SC, Rahn K, Renwick SA, Sandhu KA, Alves D, Karmali MA, Lior H, McEwen SA, Spika JS, and Gyles CL (1996):** Growing concerns and recent outbreaks involving non-O157:H7 serotypes of verotoxigenic *Escherichia coli*. *J. Food Prot*, 59:1112-1122.
- Johnson-Henry K, Wallace JL, Basappa NS, Soni R, Wu GK, and Sherman PM (2001):** Inhibition of attaching and effacing lesion formation following enteropathogenic *Escherichia coli* and Shiga toxin-producing *E. coli* infection. *Infect Immun*, 69: 7152- 7158.
- Jones NL, Islur A, Haq R, Mascarenhas M, Karmali MA, Perdue MH, Zanke BW, and Sherman PM (2000):** *Escherichia coli* Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. *Am J Physiol*, 278: 811- 819.
- Jones TF, McMillian MB and Scallan E (2007):** A population-based estimate of the substantial burden of diarrhoeal disease in the United States; FoodNet, 1996–2003. *Epidemiol Infect* 2007; 135:293–301.
- Juan C. Stockert, Alfonso Blázquez-Castro, Magdalena Cañete, Richard W. Horobin and Ángeles Villanueva (2012):** MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets Original Research Article *Acta Histochemica*, In Press, Corrected Proof, Available online 15 February 2012.
- Judge NA, Mason HS, and O'Brien AD (2004):** Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of *Escherichia coli* O157:H7 shedding in feces. *Infect Immun*, 72(1): 168: 75.
- Just I, Selzer J, von Eichel-Streiber C and Aktories K (1995):** "The low molecular mass GTP-binding protein Rho is affected by toxin A from *Clostridium difficile*". *J. Clin. Invest.* 95 (3): 1026–31. doi:10.1172/JCI117747. PMC 441436. PMID 7883950.

-
- Kaper JB, Morris JG, and Levine MM (1995):** Cholera. Clin Microbiol Rev, 8 (1): 48-86.
- Karama M (2009):**CL. Methods for genotyping verotoxin-producing *Escherichia coli*. Zoonoses Public Health 2009;56 (in press).
- Karmali M . A . (1989):** Infection by verocytotoxin producing E coli clinical microbiology rev . 2, 15- 38
- Karch H, Strockbine NA, and O'Brien AD (1986):** Growth of *Escherichia coli* in the presence of trimethoprim- sulfamethoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay. FEMS Microbiol Lett, 35: 141-45.
- Karch, H., Bielaszewska, M., Bitzan, M and Schmidt, H., (1999):** Epidemiology and diagnosis of Shiga toxin-producing *Escherichia coli* infections. Diagn. Microbiol. Infect. Dis. 34, 229–243.
- Karpman, D., H. Connell, M. Svensson, F. Schentz, P. Alm, and C. Svanborg. (1997):** The role of lipopolysaccharide and Shiga toxin in a mouse model of *Escherichia coli* O157. H7 infection. J. Infect. Dis. 175:611–620.
- Katz DA, Lynch ME and Littenberg B (1996):** "Clinical prediction rules to optimize cytotoxin testing for *Clostridium difficile* in hospitalized patients with diarrhea". Am. J. Med. 100 (5): 487–95. doi:10.1016/S0002-9343(95)00016-X. PMID 8644759.
- Kehl SC (2002):** Role of the laboratory in the diagnosis of enterohemorrhagic *Escherichia coli* infections. J Clin Microbiol, 40 (8): 2711-2751.
- Kelly, C (2011):** "Probiotics in *clostridium difficile* Infection.". Journal of clinical gastroenterology 45 Suppl: S154-8. PMID 21992956.
- Kesty NC, Manson KM, Reedy M, Miller SE, and Kuehn MJ (2004):** Enterotoxigenic *Escherichia coli* vesicles target toxin delivery into mammalian cells. EMBO J, 23 (23): 4538-49.

-
- Keusch, G. T., and M. Jacewicz. (1977):** Pathogenesis of *Shigella* diarrhea. VII: Evidence for a cell membrane toxin receptor involving $\square$ -1-4 linked N-acetyl-D-glucosamine oligomers. J. Exp. Med. 146:535–546
- Khan, M. U., N. C. Roy, R. Islam, I. Huq, and B. Stoll. 1985. Fourteen years of shigellosis in Dhaka:** An epidemiological analysis. Int. J. Epidemiol. 14:607–613
- Khan MA and Steiner TS (2002):** Mechanisms of emerging diarrheagenic *Escherichia coli* infection. Curr Infect Dis Rep, (4): 112-117.
- King CK, Glass R, Bresee JS and Duggan C (2003):** Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR, Recommendation and Reports, 52 (16): 1-16.
- Klein EJ, Kapoor D and Shugerman RP (2004):** The diagnosis of intussusception. Clin Pediatr (Phila) 2004;43:343–347.
- Konadu E, Robbins JB, Shiloach J, Bryla DA, and Szu SC (1994):** Preparation, characterization, and immunological properties in mice of *Escherichia coli* O157 O-specific polysaccharide-protein conjugate vaccines. Infect Immun, 62:5048-5054.
- Koneman, E.W., Allen, S.D., Janda, M. W., Schreckenberger, R.C. and Winn, W.C. (1997):** Introduction to microbiology. Part II: Guidelines for the collection, transport, processing, analysis and reporting of cultures from specific specimen source. In: Koneman E.W., Allen S.D., Janda M.W., Schreckenberger R.C. and Winn W.C. (eds). Color atlas and text book of diagnostic microbiology. 5th edition. Lippincott, Philadelphia. P.121-170.
- Kongmuang U, Luk JMC, and Lindberg AA (1994):** Comparison of three stool-processing methods for detection of *Salmonella* serogroups B, C2, and D by PCR. J Clin Microbiol, 32: 3072-3074.
- Kopecko, D. J., O. Washington, and S. B. Formal. (1980):** Genetic and physical evidence for plasmid control of *Shigella sonnei* Form I cell surface antigen. Infect. Immun. 29:207–214.

-
- Koster, F., J. Levin, L. Walker, K. S. Tung, R. H. Gilman, M. M. Rahaman, M. A. Majid, S. Islam, and R. C. Williams Jr. (1978):** Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. *N. Engl. J. Med.* 298:927–933.
- Kotloff KL, Winickoff JP, and Ivanoff B (1999):** Global burden of *Shigella* infections, implication for vaccine development and implementation of control strategies. *Bull WHO*, 77: 651-666.
- Kurioka T, Yunou Y, Harada H, and Kita E (1999):** Efficacy of antibiotic therapy for infection with Shiga-like toxin producing *Escherichia coli* O157:H7 in mice with protein calorie malnutrition. *Eur J Clin Microbiol Infect DIS*, 18: 561-571.
- Lan R, Alles MC, Donohoe K, Martinez MB, and Reeves PR (2004):** Molecular Evolutionary Relationships of Enteroinvasive *Escherichia coli* and *Shigella* spp. *Infect Immun*, 72(6): 5080-5088.
- Lara-Tejero M, and Galan JE (2001):** CdtA, CdtB, and CdtC form a tripartite complex that is required for cytolethal distending toxin activity. *Infect Immun*, 69:4358-4365.
- Laughon, B. E. (1988):** Prevalence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. *Gastroenterol.* 94:984–993.
- Lawler LV and Wallace MR (2003):** Diagnosis and treatment of Bacterial Diarrhea. *Curr Gastroenterol Rep*, 5:287-294.
- Lawson JM (2004):** Updates on *Escherichia coli* O157: H7. *Curr Gastroenterol Rep*, 6; 297-301.
- Levine MM (1987):** *Escherichia coli* that cause diarrhea enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. *J Infect Dis*, 155:377-389.
- Levine, O. S., and M. M. Levine. (1991):** Housflies (*Musca domestica*) as mechanical vectors of shigellosis. *Rev. Infect. Dis.* 13:688–696.

-
- Levinson W (2006):** "Chapter 18. Gram-Negative Rods Related to the Enteric Tract" (Chapter). Levinson W: Review of Medical Microbiology and Immunology, 10e
- Lindberg, A. A., Phung Dac Cam, Nguyen Chan, Le Kim Phu, Dang Duc Trach, G. Lindberg, K. Karlsson, A. Kärnell, and E. Ekwall. (1991):** Shigellosis in VietNam: Sero-epidemiologic studies with use of lipopolysaccharide antigens in ELISA. Rev. Infect. Dis. 13:S231–S237.
- Lindqvist, R. (1999):** Detection of *Shigella* spp. in food with a nested PCR method, sensitivity and performance compared with a conventional culture method. J. Appl. Microbiol. 86:971–978.
- Lin JS, and Tsen HY (1999):** Development and use of polymerase chain reaction for the detection of *Salmonella Typhimurium* in stool and food samples. J Food Prot, 62:1103-1110.
- Ljungman P, Griffiths P and Paya C (2002):** Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. Apr 15 2002;34(8):1094-7.
- Loftus EV Jr (2004):** Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504–1517.
- Loo VG, Poirier L and Miller MA (2005):** A predominantly clonal multiinstitutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–2449.
- Mackenzie A and Barns G (1991):** Randomized controlled trial comparing oral and intravenous rehydration therapy in children with diarrhea. BMJ, 303: 393-396.
- Marshall WF, McLimans CA, Yu PK, Allerberger FJ, Van Scoy RE, and Anhalt JP (1990):** Results of a 6-month survey of stool culture of *Escherichia coli* O157: H7. Mayo Clin Proc, 65 (6): 884-8.

-
- Martin C., Colin P., Fanjat N (1999):** Evaluation of O157 :H7 ID, a new chromogenic medium for isolation and detection of *Escherichia coli* O157 :H7 - 9th ECCMID Berlin, 1999, March 22-24.
- Matsushita S, Yamada S, Kai A, and Kudoh Y (1993):** Invasive strains of *Escherichia coli* belonging to serotype O121: NM. J Clin Microbiol, 31:3034-3035.
- Mattar S, Mora A, and Bernal N (1997):** Prevalence of *E. coli* O157:H7 in a pediatric population in Bogota, D.C. with acute gastroenteritis. Enferm Infecc Microbiol Clin, 15(7): 364-8.
- Mattila, Eero; Anttila, Veli-Jukka; Broas, Markku; Marttila, Harri; Poukka, Paula; Kuusisto, Kaisa; Pusa, Liana; Sammalkorpi and Kari (2008):** "A randomized, double-blind study comparing *Clostridium difficile* immune whey and metronidazole for recurrent *Clostridium difficile*-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial". Scandinavian Journal of Infectious Diseases **40** (9): 1–7. doi:10.1080/00365540801964960.
- Maurelli, A. T., R. E. Fernandez, C. A. Bloch, C. K. Rode, and A. Fasano. (1998):** "Black holes" and bacterial pathogenicity: A large genomic deletion that enhances the virulence of *Shigella* spp. and Enteroinvasive *Escherichia coli*. Proc. Natl. Acad. Sci. USA 95:3943– 3948.
- McDonald LC, Killgore GE and Thompson A (2005):** An epidemic, toxin gene-variant strain of *Clostridium difficile*. N Engl J Med 2005; 353:2433–2441.
- McKee ML, Melton-Celsa AR, Moxley RA, Francis DH, and O'Brien AD (1995):** Enterohemorrhagic *Escherichia coli* O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to Hep-2 cells. Infect Immun, 63: 3739-3744.
- Meiselman MS, Cello JP and Margaretten W(1985):** Cytomegalovirus colitis. Report of the clinical, endoscopic, and pathologic findings in two patients with the acquired immune deficiency syndrome. Gastroenterology. Jan 1985;88(1 Pt 1):171-5.

-
- Menard LP and Dubreuil JD (2002):** Enteroaggregative *Escherichia coli* heat-stable enterotoxin 1 (EAST1): a new toxin with an old twist. Crit Rev Microbiol, 28(1): 43-60.
- Merrick N, Davidson B, and Fox S (1996):** Treatment of acute gastroenteritis: too much and too little care. Clin Pediatr, 35:429-35.
- Miller JR, Barrett L, Kotloff K, and Guerrant RL (1994):** A rapid diagnostic test for infectious and inflammatory enteritis. Arch Intern Med, 154:2660-2664.
- Miller FH, Ma JJ and Scholz FJ (2001):** Imaging features of enterohemorrhagic *Escherichia coli* colitis. AJR Am J Roentgenol 2001;177: 619–623.
- Mills M and Payne SM (1995):** Genetics and regulation of heme iron transport in *Shigella dysenteriae* and detection of an analogous system in *Escherichia coli* O157:H7. J Bacteriol, 177: 3004-3009.
- Moake J (2002):** Thrombotic microangiopathies. N Eng J Med, 347: 589-600.
- Momtaz O. Wasfy1, Buhari A. Oyofol, John C. David1, Tharwat F. Ismail1, Atef M. El-Gendy1, Zaynab S. Mohran1, Yehia Sultan2, and Leonard F. Peruski, Jr.1(2000):** Isolation and Antibiotic Susceptibility of *Salmonella*, *Shigella*, and *Campylobacter* from Acute Enteric Infections in Egypt U.S. Naval Medical Research Unit No. 3, Cairo; and 2Abbassia Fever Hospital, Cairo, Egypt Present address: US NAMRU No. 2, Jakarta, Indonesia Issue Date: 3-Jun-2000
- Mosmann, T., (1983):** Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65, 55–63.
- Murinda SE, Nguyen LT, Ivey SJ, Almeida RA, and Oliver SP (2003):** Novel single tube agar based test system for motility enhancement and immunocapture of *Escherichia coli* O157: H7 by H7 flagellar antigen specific antibodies. J Clin Microbiol, 40 (12): 4685-4690.
- Murphy MS (2008):** Management of bloody diarrhea in children in primary care. BMJ 2008;336:1010–1015.

Murphy JR and Heresi GP (2003): *Yersinia*. In Nelson Text book of Pediatrics, Behrman RE, Kliegman RM and Jenson HB, 17th edition, Philadelphia, WB Saunders Company, 929-931.

Naael Hussein Ali, MSc (2004): *Escherichia coli* O157:H7 Infection and Hemolytic Uremic syndrome among Iraqi Diarrheal Children Bahrain Medical Bulletin, Vol.26, No. 2, June 2004.

Nachamkin I, Allos BM, and Ho T (1998): *Campylobacter* species and Guillain-Barré syndrome. Clin Microbiol Rev, 11:555-67.

Nakano M, Iida T, Ohnishi M, Kurokawak SN, Takashi A, Tsukamoto T, Yasunaga T, Hayashi T, Honda T (2001): Association of the urease gene with enterohemorrhagic *Escherichia coli* strains irrespective of their serogroups. J Clin Microbiol, 39 (12): 4541-3.

Nataro, J. P., J. Seriwatana, A. Fasano, D. R. Maneval, L. D. Guers, F. Noriega, S. Dubovsky, M. M. Levine, and J. G. Morris Jr. (1995): Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive *Escherichia coli* and *Shigella*. Infect. Immun. 63:4721–4728.

Nataro JP and Kaper JB (1998): Diarrheagenic *Escherichia coli*. Clin Microbiol Rev, 11(1): 142-201.

Nataro JP (2005): Enteroaggregative *Escherichia coli* pathogenesis. Curr Opin Gastroenterol, 21(1): 4-8.

Navarro-Garcia F, Canizalez-Roman A, Luna J, Sears C, and Nataro JP (2001): Plasmid-encoded toxin of enteroaggregative *Escherichia coli* is internalized by epithelial cells. Infect Immun, 69(2): 1053-60.

Nester EW, Anderson DG, Evans RC, Pearsall NN, and Nester MT (2004a) (eds): Alimentary System Infections. In Microbiology A Human Perspective, 4th edition, New York, Mc Grow Hill, p597-632.

Nester EW, Anderson DG, Evans RC, Pearsall NN, and Nester MT (2004b)(eds): Identification and classification of prokaryotes. In

Microbiology A Human Perspective, 4th edition, New York, Mc Grow Hill, p 245-264.

Noviciki TJ, Daly JA, Mottice SL, and Carroll KC (2000): Comparison of sorbitol MacConkey agar and a two-step method which utilizes enzyme linked immunosorbant assay toxin testing and a chromogenic agar to detect and isolate enterohemorrhagic *Escherichia coli*. J Clin Microbiol, 38: 547-551.

O'Brien, A. D., and R. K. Holmes. (1987): Shiga and Shiga-like toxins. Microbiol. Rev. 51:206–220

O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, and Keusch GT (1992): Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol, 180:65-94.

Obrig, T. G., C. B. Louise, C. A. Lingwood, B. Boyd, L. Barley-Maloney, and T. O. Daniel. (1993): Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 268:15484–15488.

Ochoa TJ and Cleary TG (2003): *Escherichia coli*. In Nelson Text book of Pediatrics. Behrman RE, Kliegman RM and Jenson HB (eds). 17TH edition. Philadelphia, WB Saunders Company, p 921-924.

Ojeda A, Prado V, Martinez J, Arellano C, Borczyk A, Johnson W, Lior H, and Levine MM (1995): Sorbitol-negative phenotype among enterohemorrhagic *Escherichia coli* strains of different serotypes and from different sources. J Clin Microbiol, 33:2199-2201.

Old DC (1996): *Salmonella*. In Mackie and McCartney Practical Medical Microbiology, Colle JG, Fraser AG, Marmion BP and Simmons A, 14th edition, New York, Churchill Livingstone, p385-404.

Olorunshola ID, Smith SI, and Coker AO (2000): Prevalence of EHEC O157:H7 in patients with diarrhoea in Lagos, Nigeria. APMIS, 108(11): 761-3.

-
- Park CH, Vandel NM, and Hixon DL (1996):** Rapid immunoassays for detection of *Escherichia coli* O157 directly from stool specimens. J Clin Microbiol, 34: 988-990.
- Paton JC and Paton AW (1998):** Pathogenesis and diagnosis of Shiga toxin-producing *Escherichia coli* infections. Clin Microbiol Rev, 11: 450-79.
- Paton AW, Srimanote P, Woodrow MC, and Paton JC (2001):** Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxigenic *Escherichia coli* strains that are virulent for humans. Infect Immun, 69(11): 6999-7009.
- Pfeiffer L. , Herbert L. DuPont, Theresa J. Ochoa (2012):** The patient presenting with acute dysentery - A systematic review, a-Medical School, University of Texas, 6431 Fannin, Houston, TX 77030, USA , b- School of Public Health, University of Texas, 1200 Herman Pressler, 7th Floor, Houston, TX 77030, USA, Accepted 9 January 2012, Available online 13 January 2012
- Peng X, Luo W, Zhang J, Wang S, and Lin S (2002):** Rapid detection for *Shigella* species in environmental sewage by an immunocapture PCR with universal primers. Appl Environ Microbiol, 68: 2580-3.
- Phillips AD, Giron j, Hicks S, Dougan G, and Frankel G (2000):** Intimin from enteropathogenic *Escherichia coli* mediates remodelling of the eukaryotic cell surface. Microbiology 146:1333-1344.
- Pierard D, Van Etterijck R, Breynaert J, Moriau L, and Lauwers S (1990):** Results of screening for verocytotoxin-producing *Escherichia coli* in faeces in Belgium. Eur J Clin Microbiol Infect Dis, 9:198-201.
- Pichel M, Binsztein N and Viboud G (2000):** CS22, a novel human enterotoxigenic *Escherichia coli* adhesin, is related to CS15. Infect Immun, 68:3280-3285.
- Pickering LK (2003):** Approach to diagnosis and management of gastrointestinal tract infections. In Principles and Practice of Pediatric Infectious Diseases, Long SS, Pickering LK and Prober CG, 2nd edition, Churchill Livingstone, p362-368.

-
- Pickering LK and Snyder JD (2003):** Gastroenteritis. In Nelson Text book of Pediatrics, Behrman RE, Kliegman RM and Jenson HB, 17th edition, Philadelphia, WB Saunders Company, p1272-1281.
- Pitarangsi C, Serichantalergs O, and Isenbarger DW (2002):** Bacterial enteric pathogens in children with acute dysentery in Thailand: increasing importance of quinolone-resistant *Campylobacter*. Southeast Asian J Trop Med Public Health, 33(4):725-7.
- Popoff MY, Bockemuhl J, and Hickman-Brenner FW (2000):** Supplement 1998 (no. 42) to the Kauffmann-White scheme. Res Microbiol, 151: 63-65.
- Potter AA, Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, Erickson G, Hinkley S, Klopfenstein T, Moxley RA, Smith DR, and Finlay BB (2004):** Decreased shedding of *Escherichia coli* O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine, 22: 362-369.
- Punyaratabandhu, P., K. Vathanophas, W. Varavithya, R. Sangchai, S. Athipanyakom, P. Echeverria, and C. Wasi. (1991):** Childhood diarrhea in a low-income urban community in Bangkok: Incidence, clinical features and child caretaker's behaviours. J. Diarrhoeal Dis. Res. 9:244– 249.
- Quinn, T. C., Stamm, W. E., Goodell, S. E., Mkrtychian, E., Benedetti, J., Corey, L., Schuffler, M. D., Holmes K. K. (1983):** The polymicrobial origin of intestinal infections in homosexual men. N. Engl. J. Med. 309:576–582.
- Rabbani GH and Greenough WB (1999):** Food as a vehicle of transmission of cholera. J Diarrhoeal Dis Res, 17 (1): 1-9.
- Ramiro Cruz, J., F. Cano, A. V. Bartlett, and H. Mendez. (1994):** Infection, diarrhea and dysentery caused by *Shigella* species and *Campylobacter jejuni* among Guatemalan rural children. Pediatr. Infect. Dis. J. 13:216–223.

-
- Ramotar K, Henderson E, Szumski R, and Louise TJ (1995):** Impact of free verotoxin testing on epidemiology of diarrhea caused by verotoxin-producing *Escherichia coli*. J Clin Microbiol, 33 (5): 1114-20.
- Rao MR, Abu-Elyazeed R, Stephen J. Savarino SJ, ANaficy AB, Wierzba TF, Abdel-Messih I, Shaheen H, Frenck Jr RW, Svennerholm AM and Clemens JD (2003):** High disease burden of diarrhea due to enterotoxigenic *Escherichia coli* among rural Egyptian infants and young children. J Clin Microbiol, 41 (10): 4862-4864.
- Ray PE and Liu XH (2001):** Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol, 16: 823-839.
- Reischl U, Youssef MT, Wolf H, Hyytia-Trees E, and Strockbine NA (2004):** Real-time fluorescence PCR assays for detection and characterization of heat-labile I and heat-stable I enterotoxin genes from enterotoxigenic *Escherichia coli*. J Clin Microbiol, 42 (9): 4092-4100.
- Remon R. Abu-Elyazeed, Thomas F. Wierzba , Shannon D. Putnam, Malla R. RAO, Karim A. Kamal, Leonard F. Peruski JR. and Ibrahim A. Abd-EL Messih (2004):** Epidemiology of *Shigella* associated diarrhea in rural Egyptian children Received December 23, 2003. Accepted March 22, 2004.
- Rendón, M. A.; et al. (2007):** "Commensal and pathogenic *Escherichia coli* use a common pilus adherence factor for epithelial cell colonization". PNAS 104 (25): 10637–42. doi:10.1073/pnas.0704104104. PMC 1890562. PMID 17563352
- Richardson SE, Karmali MA, Becker LE, and Smith CR (1988):** The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing *Escherichia coli* infections. Hum Pathol, 19:1102-1108.
- Ries, A. A. Wells, J. G., Olivola, D., Ntakibirora, M., Nyandwi, S., Ntibakitayo, M., Ivey, C. B., Greene, K. D., Tenover, F. C., Wahlquist, S. P. (1994):** Epidemic *Shigella dysenteriae* type 1 in Burundi: Persistence and implications for prevention. J. Infect. Dis. 169:1035–1041

-
- Ritchie JM, Thrope CM, Rogers AB, and Waldor MK (2003):** Critical roles of stx2, eae, and tir in enterohemorrhagic *Escherichia coli* –induced diarrhea and intestinal inflammation in infant rabbits. *Infect Immun*, 71 (12):7129-7139.
- Robins-Browne RM and Hartland E (2002):** Advances in pediatric gastroenterology and hepatology. *Escherichia coli* as a cause of diarrhea. *J Gastroenterol Hepatol*, 17: 467-475.
- Rodney A. Welch (2006):** The Genus *Escherichia*. *Prokaryotes* (2006) CHAPTER 3.3.3 6:60–71 DOI: 10.1007/0-387-30746-x_3 .
- Römer W, Berland L and Chambon V (2007):** "Shiga toxin induces tubular membrane invaginations for its uptake into cells". *Nature* 450 (7170): 670–5. doi:10.1038/nature05996. PMID 18046403.
- Ryan KJ and Ray CG (2004):** Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 322–4. ISBN 0-8385-8529-9.
- Sack, R. B., M. Rahman, M. Yunus, and E. H. Khan. (1997):** Antimicrobial resistance in organisms causing diarrhoeal disease. *Clin. Infect. Dis.* 24:S102–S105.
- Safaa MA (2005):** *Escherichia coli* O157: H7 in acute childhood diarrhea . Microbiology and immunology thesis, Ain Shams University Hospitals.
- Safdar N, Said A, Gangson RE, and Maki DG (2002):** Risk of hemolytic uremic syndrome after antibiotic treatment of *Escherichia coli* O157: H7 enteritis. A Meta-analysis. *JAMA*, 228 (8): 996-1001.
- Salmnzadeh-Ahrabi S, Habibi E, Jaafari F, and Zali MR (2005):** Molecular epidemiology of *Escherichia coli* diarrhea in children in Tahrán. *Ann Trop Paediatr*, 25 (1): 35-9.
- Sandvig, K., K. Prydz, M. Ryd, and B. Van Deurs. (1991):** Endocytosis and intracellular transport of the glycolipidbinding ligand Shiga toxin in polarized MDCK cells. *J. Cell Biol.* 108:553–562.

-
- Sansonetti, P. J., M. David, and M. Toucas. (1980):** Correlation entre la perte d'ADN plasmidique et le passage de la phase I virulente à la phase II avirulente chez *Shigella sonnei*. C. R. Acad. Sci. 290:879–882.
CHAPTER 3.3.6 The Genus *Shigella* 121
- Sansonetti, P. J., D. J. Kopecko, and S. B. Formal. (1982):** Involvement of a plasmid in the invasive ability of *Shigella flexneri*. Infect. Immun. 35:852–860.
- Sartor RB (2005):** Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol, 21(1): 44-50.
- Savarino SJ, McVeigh A, Watson J, Molina J, Cravioto A, Echeverria P, Bhan MK, Levine MM, and Fasano A (1996):** Enteroaggregative *Escherichia coli* heat-stable enterotoxin is not restricted to enteroaggregative *Escherichia coli*. J Infect Dis, 173:1019-1022.
- Savidge, Tor C; Urvil, Petri; Oezguen, Numan; Ali, Kausar; Choudhury, Aprateem; Acharya, Vinay; Pinchuk, Irina; Torres and Alfredo G (2011):** "Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins". Nature Medicine 17 (9): 1136–41. doi:10.1038/nm.2405. PMC 3277400. PMID 21857653. Lay summary – ScienceDaily (August 21, 2011).
- Saxelin M, Tynkkynen S, Mattila-Sandholm T, and de Vos WM (2005):** Probiotic and other functional microbes: from markets to mechanisms. Curr Opin Biotechnol, 16(2): 204-11
- Saxena, S. K., A. D. O'Brien, and E. J. Ackerman. (1989):** Shiga toxin, Shiga-like toxin II variant, and ricin are all singlensite N-glycosidases of 28S RNA when microinjected into *Xenopus* oocytes. J. Biol. Chem. 264:596–601
- Scaletsky ICA, Fabbricotti SHF, Carvalho RLB, Nunes CR, Maranh HS, Morais MB, and Fagundes-Neto U (2002):** Diffusely Adherent *Escherichia coli* as a Cause of Acute Diarrhea in Young Children in Northeast Brazil: a Case-Control Study. J Clin Microbiol, 40(2): 645–648.

-
- Schmidt H and Hensel M (2004):** Pathogenicity islands in bacterial pathogenesis. Clin Microbiol Rev, 17 (1): 14-56.
- Schmidt H, and Karch H (1996):** Enterohemolytic phenotypes and genotypes of Shiga toxin-producing *Escherichia coli* O111 strains from patients with diarrhea and hemolytic uremic syndrome. J Clin Microbiol, 34:2364-2367.
- Schmidt H, Montag M, Bockemühl J, Heesemann J, and Karch H (1993):** Shiga-like toxin II-related cytotoxins in *Citrobacter freundii* strains from humans and beef samples. Infect Immun, 61:534-543.
- Sears CL, and Kaper JB (1996):** Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev, 60:167-215.
- Seear MD (eds) (2000):** Child with vomiting, diarrhea, and abdominal pain. In Manual of Tropical Pediatrics, 1st edition, Cambridge University Press, p126-154.
- Sekizaki, T., S. Harayama, and K. N. Timmis. (1987):** Genetic manipulation in vivo of stx, a determinant essential for high level production of Shiga toxin by *Shigella dysenteriae* serotype 1: Localization near pyrF and generation of Stx-transposon mutants. Infect. Immun. 55:2208–2214.
- Sethabutr, O., M. Venkatesan, G. S. Murphy, B. Eampokolab, C. V. Hoge, and P. Echeverria. (2004):** Detection of *shigellae* and enteroinvasive *Escherichia coli* by amplification of the invasion plasmid antigen HDNA sequence in patients with dysentery. J. Infect. Dis. 162:458–461.
- Sharp, T. W., S. A. Thornton, M. R. Wallace, R. F. Defraites, J. L. Sanchez, R. A. Batchelor, P. J. Rozmajzl, R. K. Hanson, P. Echeverria, and A. Z. Kapikian. (1995):** Diarrheal disease among military personnel during Operation Restore Hope, Somalia, 1992–1993. Am. J. Trop. Med. Hyg. 52:188–193.
- Shebib ZA, Abdul Ghani ZG, and Mahdi LK (2003):** First report of *Escherichia coli* O157 among Iraqi children. East Mediterr Health J, 9(1-2): 159-66.

-
- Shehabi AA, Bulos NK, and Hajjaj KG (2003):** Characterization of diarrheagenic *Escherichia coli* isolates in Jordanian children. *Scan J Infect Dis*, 35 (6): 368-71.
- Sheikh J, Hicks S, Dall'Agnol M, Phillips AD, and Nataro JP (2001):** Roles for Fis and YafK in biofilm formation by enteroaggregative *Escherichia coli*. *Mol Microbiol* 41(5): 983-97.
- Sheth KJ, Gill JC, and Hanna J (1988):** Failure of fresh frozen plasma infusions to alter the course of hemolytic-uremic syndrome. *Child Nephrol Urol*, 9:38-41.
- Siegel D, Cohen PT and Neighbor M (1987):** Predictive value of stool examination in acute diarrhea. *Arch Pathol Lab Med* 1987;111: 715–718
- Simmons, D. A. R., and E. Romanowska. (1987):** Structure and biology of *Shigella flexneri* O antigens. *J. Med. Microbiol.* 23:289–302.
- Sirinavin S and Garner P (2000):** Antibiotics for treating *salmonella* gut infections. *Cochrane Database Syst Rev* 2000;(2):CD001167
- Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, and Griffin PM (1997):** *Escherichia coli* O157:H7 diarrhea in the United States: clinical and epidemiologic features. *Ann Intern Med*,126(7):505-13.
- Smith TF, Espy MJ, Mandrekar J, Jones MF, Cockerill FR and Patel R (2007):** Quantitative real-time polymerase chain reaction for evaluating DNAemia due to *cytomegalovirus*, *Epstein-Barr* virus, and *BK* virus in solid-organ transplant recipients. *Clin Infect Dis.* Oct 15 2007;45(8):1056-61.
- Speights VO, Johnson MW, Stoltenberg PH, Rappaport ES, Helbert B and Riggs M (1991):** Colorectal cancer: current trends in initial clinical manifestations. *South Med J* 1991;84:575–578.
- Stagno S (2001):** *Cytomegalovirus*. In: Remington JS, Klein JO. *Infectious Diseases of the Fetus and Newborn Infant*. Philadelphia: WB Saunders; 2001:389-424.

-
- Stapp JR, Jelacie S, Yea Y, Klein EJ, Fischer M, Clausen CR, Qin X, Swerdlow DL, and Tar PI (2000):** Comparison of *Escherichia coli* O157:H7 antigen detection in stool and broth cultures to that in Sorbitol MacConkey agar stool cultures. *J Clin Microbiol*, 38: 3403-3406.
- Stechman M, Safranek P and Purkayastha S (2004):** Intussusception in a young adult with bloody diarrhoea. *Int J Surg* 2004;2:121–122.
- Steffen R (2005):** Epidemiology of traveler's diarrhea. *Clin Infect Dis* 2005;41(Suppl 8):S536–S540.
- Steiner TS, Nataro JP, Poteet-Smith CE, Smith JA, and Guerrant RL (2000):** Enteroaggregative *Escherichia coli* expresses a novel flagellin that causes IL-8 release from intestinal epithelial cells. *J Clin Investig*, 105:1769-1777.
- Stoll, B. J., R. I. Glass, M. I. Huk, M. U. Khan, H. Banu, and J. Holt. (1982):** Epidemiologic and clinical features of patients infected with *Shigella* who attended a diarrheal disease hospital in Bangladesh. *J. Infect. Dis.* 146:177– 183.
- Stroehlein J (2004):** "Treatment of *Clostridium difficile* Infection". *Curr Treat Options Gastroenterol* 7 (3): 235–239. doi:10.1007/s11938-004-0044-y. PMID 15149585.
- Sturrock RF (2001):** The Schistosomiasis and their intermediate hosts. In: Mahmood AAF. *Schistosomiasis*. Imperial College London; 2001:7-83.
- Struelens, M. J., D. Patte, I. Kabir, A. Salam, S. K. Nath, and T. Butler. (2006):** *Shigella* septicemia: Prevalence, presentation, risk factors, and outcome. *J. Infect. Dis.* 152:784– 790.
- Sugai M, Kawamoto T, Pérès SY, Ueno Y, Komatsuzawa H, Fujiwara T, Kurihara H, Suginaka H, and Oswald E (1998):** The cell cycle-specific growth-inhibitory factor produced by *Actinobacillus actinomycetemcomitans* is a cytolethal distending toxin. *Infect Immun*, 66:5008-5019.
- Sullivan A and Nord CE (2005):** Probiotics and gastrointestinal diseases. *J Intern Med*, 257(1):78-92.

-
- Sur D, Ramamurthy T, Deen J and Bhattacharya SK (2004):** Shigellosis: challenges & management issues. *Indian J Med Res*, 120: 454-462.
- Suttorp N, Flöer B, Schnittler H, Seeger W, and Bhakdi S (1990):** Effects of *Escherichia coli* hemolysin on endothelial cell function. *Infect Immun*, 58:3796-3801.
- Szakal D, Gado I, and Pal T (2003):** A colony blot immunoassay to detect enteroinvasive *Escherichia coli* and *Shigella* in water samples. *J Appl Microbiol*, 90 (2): 229-36.
- Tarr PI (1995):** *Escherichia coli* O157: H7: clinical, diagnostic, and epidemiological aspects of human infection. *Clin Infect Dis*, 20 (1): 201-208.
- Tarr PI, Bilge SS, Vary JC, Jelacic S, Habeeb RL, Ward TR, Baylor MR, and Besser TE (2000):** Iha: a novel *Escherichia coli* O157:H7 adherence-conferring molecule encoded on a recently acquired chromosomal island of conserved structure. *Infect Immun*, 68: 1400-1407.
- Tarr PI, and Neill MA (1996):** Perspective: The problem of non-O157: H7 Shiga toxin (verocytotoxin)-producing *Escherichia coli*. *J Infect Dis*, 174:1136-1139.
- Tatsuno I, Horie M, and Abe H (2001):** Tox B gene on *pO157* of enterohemorrhagic *Escherichia coli* O157:H7 is required for full epithelial cells adherence phenotype. *Infect Immun*, 69: 3315-3322.
- Tauxe, R. V., R. C. Mabnald, N. Hargrett-Bean, and P. A. Black. (1988):** The persistence of *Shigella* fever in the United States: The increased role of the adult male. *Am. J. Public Health* 78:1432–1435
- Tauxe, R. V., N. D. Puhr, J. G. Wells, N. Hargrett-Bean, and P. A. Blake. (1990):** Antimicrobial resistance of *Shigella* isolates in the USA: The importance of international travellers. *J. Infect. Dis.* 162:1107–1111.
- Tenover, F. C. (1989):** DNA probes for bacterial stool pathogens. In: F. C. Tenover (Ed.) *DNA Probes for Infectious Diseases*. CRC Press. Boca Raton, FL. 53–63.